# US Insulin Delivery Devices Market

> US Insulin Delivery Devices Market Research Report: Size, Share, Trend Analysis By Device Type (Insulin Pens, Insulin Pumps, Smart Insulin Delivery Devices, Insulin Syringes), By Technological Advancement (Conventional, Automated, Continuous Glucose Monitoring Integrated, Patch Style), By End Users (Hospitals, Home Care, Diabetes Clinics, Research Institutes) and By Patient Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.15%
- **2024:** $ 3,709.79 Million
- **2025:** $ 3,900.84 Million
- **2035:** $ 6,445.22 Million
- **Key Players:** Medtronic (US), Abbott (US), Roche (CH), Insulet (US), Novo Nordisk (DK), Sanofi (FR), Becton Dickinson (US), Ypsomed (CH), Tandem Diabetes (US)

**Report ID:** MRFR/MED/18411-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-insulin-delivery-devices-market-19958

---

## Market Summary

## **US Insulin Delivery Devices Market Overview**

As per MRFR analysis, the US Insulin Delivery Devices Market Size was estimated at 2.17 (USD Billion) in 2023. The US Insulin Delivery Devices Market Industry is expected to grow from 2.5(USD Billion) in 2024 to 4 (USD Billion) by 2035. The US Insulin Delivery Devices Market CAGR (growth rate) is expected to be around 4.365% during the forecast period (2025 - 2035).

### **Key US Insulin Delivery Devices Market Trends Highlighted**

The US Insulin Delivery Devices Market has been experiencing significant changes driven by various factors. One major market driver is the increasing prevalence of diabetes in the country. The Centers for Disease Control and Prevention (CDC) reports that diabetes affects millions of Americans, resulting in a growing demand for effective insulin delivery solutions.

Furthermore, there is a strong push towards technological advancement in insulin delivery devices, including the introduction of smart pens and continuous glucose monitoring systems. These innovations enhance the convenience and precision of insulin administration, appealing to both healthcare providers and patients.

Opportunities within the market are emerging particularly from the rise of telehealth services in the United States. Telehealth has gained traction, especially during and after the pandemic, allowing patients to manage their diabetes remotely and access healthcare providers without the need for in-person visits.

This trend opens avenues for the integration of digital health solutions with insulin delivery devices, catering to the needs of a tech-savvy patient population. Recently, there has been a notable trend in patient-centric solutions that focus on user experience. Devices are being designed with an emphasis on comfort, ease of use, and portability, encouraging adherence to treatment regimens.

Additionally, regulatory bodies such as the FDA are supporting the development and approval of innovative insulin delivery technologies, fostering a competitive environment in the market. As healthcare continues to evolve, the incorporation of data analytics and smartphone applications in insulin management presents further possibilities for manufacturers to explore, enhancing the overall treatment experience for diabetes patients in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Insulin Delivery Devices Market Drivers**

### **Rising Diabetes Prevalence**

The increasing prevalence of diabetes in the United States is a key driver of growth in the US [Insulin Delivery Devices Market](../../../reports/insulin-delivery-devices-market-851) Industry. According to the Centers for Disease Control and Prevention (CDC), over 34 million Americans, or approximately 10.5% of the population, have diabetes. This statistic underscores the urgent need for effective management solutions, such as insulin delivery devices.

Furthermore, the National Diabetes Statistics Report indicates a steady rise in diabetes cases, which is expected to increase demand for various insulin delivery methods, including insulin pens, pumps, and inhalers. Organizations like the American Diabetes Association are actively promoting awareness and better management solutions, further supporting this market growth.

The increasing number of diabetes patients necessitates the development and distribution of more advanced insulin delivery devices, propelling the overall market forward.

### **Technological Advancements in Delivery Devices**

Technological innovations in insulin delivery devices are a significant driver for the US Insulin Delivery Devices Market Industry. For instance, the development of smart insulin pens and continuous glucose monitoring systems has transformed diabetes management. According to the Food and Drug Administration (FDA), a surge in the approval of advanced delivery devices highlights the ongoing Research and Development efforts in this sector.

Companies such as Medtronic and Eli Lilly are leading the charge with innovative products that enhance user comfort and regulatory compliance, supporting market growth. The adoption of technology in diabetes care continues to rise among patients, creating a substantial impact on the demand for sophisticated insulin delivery systems.

### **Government Initiatives and Funding**

Government initiatives aimed at improving diabetes care and funding research related to insulin delivery devices play a crucial role in the growth of the US Insulin Delivery Devices Market Industry. The National Institutes of Health (NIH) invests hundreds of millions each year in diabetes research, which includes finding better insulin delivery mechanisms.

Such investment is vital as it spurs innovation and ensures the development of more effective and accessible devices for the growing patient population. Moreover, initiatives like the CDC's National Diabetes Prevention Program aim to provide resources for individuals at risk of diabetes, thereby encouraging the market for sophisticated delivery solutions.

The backing from governmental bodies boosts industry confidence and supports the financial viability of emerging technologies in this space.

## **US Insulin Delivery Devices Market Segment Insights**

### **Insulin Delivery Devices Market Device Type Insights**

The US Insulin Delivery Devices Market focuses significantly on various device types that cater to the needs of individuals with diabetes. This segmentation primarily includes Insulin Pens, Insulin Pumps, Smart Insulin Delivery Devices, and Insulin Syringes, each of which plays a vital role in the management of blood glucose levels. Insulin Pens have become increasingly popular due to their convenience and ease of use, allowing patients to manage their diabetes effectively without the need for complex setups.

Insulin Pumps offer the advantage of continuous insulin delivery, which mimics the physiological insulin supply and helps maintain better glucose control, proving essential for patients requiring precise dosing adjustments. Smart Insulin Delivery Devices incorporate advanced technologies that enable real-time monitoring and data recording, making them indispensable in the era of personalized medicine.

They promote better patient engagement by syncing with mobile applications, providing insights that aid in decision-making and enhancing adherence to prescribed regimens. On the other hand, Insulin Syringes continue to hold importance, particularly among users who prefer traditional methods of insulin delivery, characterized by their simplicity and cost-effectiveness.

This variety in device types reflects the diverse preferences and needs of patients in the United States, supporting the overall growth of the insulin delivery devices segment. Growing awareness about diabetes management and advancements in technology are significant drivers for this market segment.

Moreover, as the population of diabetes patients continues to rise, facilitated by increasing obesity rates and sedentary lifestyles, the demand for these devices is expected to grow. However, it is essential to navigate the challenges associated with technology adoption, including cost factors and the necessary user education that accompanies sophisticated devices.

In conclusion, the Device Type landscape in the US Insulin Delivery Devices Market showcases an essential trend towards convenience, innovation, and efficiency, substantially impacting diabetes care and management in the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Insulin Delivery Devices Market Technological Advancement Insights**

The Technological Advancement segment of the US Insulin Delivery Devices Market has been instrumental in transforming the management of diabetes. The market has experienced significant growth, driven by innovations enhancing patient convenience and adherence to treatment. Among the emerging solutions, Conventional devices remain foundational, but the shift towards Automated and Continuous Glucose Monitoring Integrated devices illustrates a growing preference for convenience and precision in diabetes management.

Automated systems reduce the burden of manual insulin administration, while Continuous Glucose Monitoring devices provide real-time data, enabling better glycemic control. Additionally, Patch Style devices, which offer a discreet and user-friendly alternative for insulin delivery, are gaining traction due to their ease of use and enhanced patient experience.

This segment reflects the overall trend towards technology integration in healthcare, aimed at improving patient outcomes and simplifying complex treatment regimens. As the US population grapples with rising diabetes prevalence, the emphasis on innovation within this market segment is crucial for meeting patient needs and addressing broader health challenges.

The evolution of these technologies underscores the commitment to improving quality of life for individuals living with diabetes in the US.

### **Insulin Delivery Devices Market End User Insights**

The End User segment of the US Insulin Delivery Devices Market plays a pivotal role in the overall growth and transformation of diabetes management. Hospitals constitute a significant portion of this segment, facilitating access to advanced insulin delivery technologies and offering comprehensive care for patients with varying levels of diabetes severity.

Home care is emerging as a crucial area due to the increasing preference for patient-centric solutions, allowing for diabetes management in a familiar environment and leading to better adherence and outcomes. Diabetes clinics provide specialized services geared towards education and support, catering to the specific needs of diabetic patients while promoting regular monitoring and usage of insulin delivery devices.

Research Institutes are instrumental in driving innovation and development of new technologies, contributing to the continuous enhancement of insulin delivery solutions. The emphasis on patient-centered care and technological advancements is expected to further propel the growth of this segment, creating opportunities for improved treatment outcomes and quality of life for patients across the US.

### **Insulin Delivery Devices Market Patient Type Insights**

The US Insulin Delivery Devices Market exhibits significant diversity in its Patient Type segmentation, encompassing Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Type 1 Diabetes is a critical segment, primarily affecting children and young adults, and often requires intensive insulin therapy; advancements in technology have made insulin pumps and continuous glucose monitoring systems essential for effective management.

Type 2 Diabetes, which is highly prevalent in the United States, is driven by lifestyle factors, and the demand for user-friendly delivery devices is rapidly growing as more adults seek convenient alternatives for insulin administration. Gestational Diabetes, although less common, holds importance due to the potential health risks posed to both mothers and children; effective insulin delivery systems are pivotal in managing this condition, especially during pregnancy.

Collectively, these segments demonstrate the varied needs of insulin-dependent patients and underscore the market's role in addressing diverse healthcare demands through innovative delivery solutions. The evolving landscape of diabetes management continues to drive the US Insulin Delivery Devices Market, with increasing emphasis on personalized treatment options to enhance patient quality of life.

## **US Insulin Delivery Devices Market Key Players and Competitive Insights**

The US Insulin Delivery Devices Market is characterized by a multitude of players striving to provide innovative solutions for diabetes management. With an increasing prevalence of diabetes and a growing demand for effective and user-friendly delivery systems, the market has witnessed significant advancements in technology. To remain competitive, companies are focusing on product differentiation, improved patient adherence, and integration with digital health solutions.

Additionally, the landscape is influenced by factors such as regulatory changes, reimbursement policies, and patient preferences, which ultimately shape the strategies employed by key market players. As competition heats up, firms are investing in research and development to enhance their product offerings, aiming to capture a larger share of this lucrative market.

Ypsomed has established a notable presence in the US Insulin Delivery Devices Market by providing a range of innovative and high-quality solutions tailored for diabetes management. The company is recognized for its cutting-edge technologies, such as advanced pen systems and connected insulin delivery devices that enhance patient convenience and compliance.

Additionally, Ypsomed emphasizes user-centric design, ensuring that their products are not only effective but also easy for patients to interact with. The company has built strong partnerships with various stakeholders within the healthcare ecosystem, enabling it to expand its reach and enhance its market presence in the US. Its focus on continual innovation and dedication to improving patient outcomes fortify Ypsomed's position in a highly competitive industry.

Becton Dickinson (BD) operates as a significant player in the US Insulin Delivery Devices Market, offering a wide array of products, including insulin syringes, pen needles, and safety-engineered devices. The company's commitment to quality and safety has bolstered its reputation in the diabetes care landscape, positioning it as a trusted choice among healthcare professionals and patients alike.

BD boasts a strong market presence backed by its extensive distribution networks and solid partnerships with healthcare providers. The company's strengths also extend to its robust portfolio of medical technologies that cater to diabetes management. Furthermore, Becton Dickinson has engaged in strategic mergers and acquisitions to bolster its product offerings and market reach, ensuring that it continues to innovate and address the evolving needs of diabetes patients in the US.

Through continuous investment in research and development, BD remains focused on enhancing its capabilities to deliver effective solutions tailored for the unique needs of the US diabetes population.

### **Key Companies in the US Insulin Delivery Devices Market Include**

- Ypsomed
- Becton Dickinson
- Aspirion
- Eli Lilly
- Roche
- AbbVie
- Zylera
- Insulet Corporation
- Terumo
- **[Sanofi](https://www.sanofi.com/en/india/our-science/pharmaceutical-products)**
- Dexcom
- Novo Nordisk
- Tandem Diabetes
- Medtronic

## **US Insulin Delivery Devices Market Industry Developments**

The US Insulin Delivery Devices Market has witnessed significant advancements and developments recently. In August 2023, Medtronic announced its latest innovation in insulin delivery with the launch of the MiniMed 780G system, which offers automated insulin delivery to improve glycemic control in patients with diabetes.

Meanwhile, in June 2023, Dexcom introduced its G7 Continuous Glucose Monitoring system, further enhancing diabetes management through seamless integration with insulin delivery devices. Notably, in July 2023, Becton Dickinson completed its acquisition of the digital health company Atrial Medical, aiming to expand their portfolio in diabetes care.

A substantial valuation growth has been observed in companies such as Eli Lilly, which has significantly increased its market share due to its advancements in insulin formulations. The market has also seen mergers and collaborations to enhance research and development capabilities, as seen with Novo Nordisk’s partnership with Insulet Corporation.

The increasing prevalence of diabetes in the US has driven innovation and investment in insulin delivery technologies, reflecting strong growth in this critical sector of healthcare.

## **US Insulin Delivery Devices Market Segmentation Insights**

### **Insulin Delivery Devices Market Device Type Outlook**

- Insulin Pens
- Insulin Pumps
- Smart Insulin Delivery Devices
- Insulin Syringes

### **Insulin Delivery Devices Market Technological Advancement Outlook**

- Conventional
- Automated
- Continuous Glucose Monitoring Integrated
- Patch Style

### **Insulin Delivery Devices Market End User Outlook**

- Hospitals
- Home Care
- Diabetes Clinics
- Research Institutes

### **Insulin Delivery Devices Market Patient Type Outlook**

- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes

## Market Drivers

### Rising Diabetes Prevalence

The increasing prevalence of diabetes in the United States is a primary driver for the insulin delivery-devices market. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, have diabetes. This growing patient population necessitates effective insulin management solutions, thereby propelling demand for advanced delivery devices. As the number of individuals diagnosed with diabetes continues to rise, the insulin delivery-devices market is expected to expand significantly. Furthermore, the aging population, which is more susceptible to diabetes, contributes to this trend. The need for reliable and user-friendly insulin delivery systems is paramount, as patients seek to manage their condition effectively and maintain a good quality of life.

### Growing Awareness and Education

There is a notable increase in awareness and education regarding diabetes management among patients and healthcare professionals, which is positively influencing the insulin delivery-devices market. Educational initiatives by organizations and healthcare providers are equipping patients with the knowledge necessary to manage their diabetes effectively. This heightened awareness leads to increased adoption of insulin delivery devices, as patients become more informed about their options. Furthermore, the emphasis on self-management and patient empowerment is driving demand for user-friendly devices that facilitate better control of blood glucose levels. As a result, the insulin delivery-devices market is likely to experience growth as more patients seek out these solutions to improve their health outcomes.

### Supportive Reimbursement Policies

Supportive reimbursement policies in the United States are playing a crucial role in the growth of the insulin delivery-devices market. Insurance coverage for advanced insulin delivery systems, including insulin pumps and smart pens, is becoming more prevalent, making these devices more accessible to patients. The Centers for Medicare & Medicaid Services (CMS) and private insurers are increasingly recognizing the importance of these devices in managing diabetes effectively. As reimbursement policies evolve to support innovative technologies, patients are more likely to invest in insulin delivery devices that enhance their quality of life. This trend is expected to drive market growth, as financial barriers are reduced, allowing for broader adoption of advanced insulin delivery solutions.

### Increased Focus on Preventive Healthcare

The growing emphasis on preventive healthcare in the United States is influencing the insulin delivery-devices market. Healthcare providers are increasingly advocating for proactive management of diabetes to prevent complications associated with the disease. This shift towards preventive care encourages patients to utilize insulin delivery devices that facilitate better glucose control and reduce the risk of long-term health issues. As healthcare systems prioritize preventive measures, the demand for effective insulin delivery solutions is likely to rise. This trend aligns with broader public health goals aimed at reducing the burden of diabetes on the healthcare system, thereby fostering growth in the insulin delivery-devices market.

### Technological Innovations in Delivery Systems

Technological advancements in insulin delivery devices are transforming the insulin delivery-devices market. Innovations such as smart insulin pens, continuous glucose monitors (CGMs), and automated insulin delivery systems are enhancing patient experience and adherence to treatment. For instance, the integration of mobile applications with insulin delivery devices allows for real-time monitoring and data sharing with healthcare providers. This trend is likely to improve patient outcomes and satisfaction. The market for insulin delivery devices is projected to reach approximately $10 billion by 2026, driven by these technological innovations. As patients increasingly demand more sophisticated and efficient solutions, manufacturers are compelled to invest in research and development to stay competitive in the evolving landscape.

## Future Outlook

The [Insulin Delivery Devices Market](https://www.marketresearchfuture.com/reports/insulin-delivery-devices-market-851) is projected to grow at a 5.15% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and enhanced patient compliance.

**New opportunities:**

- Development of integrated digital health platforms for real-time monitoring. Expansion of automated insulin delivery systems in outpatient settings. Partnerships with telehealth providers for remote patient management solutions.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Device Type: Insulin Pens (Largest) vs. Smart Insulin Devices (Fastest-Growing)

The device type segment in the US insulin delivery-devices market demonstrates a diverse landscape with insulin pens commanding the largest share. This preference is attributed to their user-friendly design and increased adoption among patients seeking convenience in their insulin delivery. Insulin syringes and pumps follow, each serving distinct patient needs, while smart insulin devices are gaining traction as technology advances.

Growth trends indicate a substantial upswing in smart insulin devices, driven by innovative features like connectivity with mobile applications and real-time glucose monitoring. As diabetes management shifts towards more integrated solutions, the market anticipates a surge in demand for these advanced devices. Additionally, the push for personalized medicine and patient engagement fosters the rapid development of smart alternatives alongside traditional delivery methods.

Insulin Pens (Dominant) vs. Smart Insulin Devices (Emerging)

Insulin pens have established themselves as the dominant device due to their ease of use, flexibility, and portability, making them a preferred choice for many diabetic patients. Their pre-filled designs and dosage accuracy cater to a broad demographic, ensuring patient compliance. Conversely, smart insulin devices represent the emerging segment that is set to revolutionize diabetes management. Equipped with advanced technology, these devices offer features like data connectivity and predictive analytics, enhancing the patient's ability to manage their condition. The growing awareness of personalized health solutions and the importance of real-time monitoring is propelling the demand for smart insulin devices, marking a significant shift in patient preferences toward more innovative and efficient management solutions.

### By End User: Hospitals (Largest) vs. Home Care Settings (Fastest-Growing)

In the US insulin delivery-devices market, hospitals represent the largest end-user segment, reflecting a significant portion of overall usage driven by the complex care and management of diabetic patients. Home care settings are gaining ground rapidly, appealing to the growing preference for self-management and convenience among patients. Diabetes clinics also play a crucial role but occupy a smaller share compared to hospitals and home care settings.

The growth trends in this segment reveal a shift towards more personalized insulin delivery solutions. Hospitals are investing heavily in advanced technology for better patient outcomes, while home care settings are benefitting from innovations in portable delivery devices. The increasing incidence of diabetes and a rising emphasis on patient-centric care are critical drivers fueling this market segment, fostering competition and technological advancements.

Hospitals (Dominant) vs. Home Care Settings (Emerging)

Hospitals stand as the dominant end-user in the market, driven by the complexity of diabetes management that requires integrated care involving multiple healthcare professionals. These institutions often utilize advanced insulin delivery systems that cater to a wide array of patient needs. In contrast, home care settings represent an emerging segment, characterized by a growing trend towards self-administration of insulin. Patients now prefer devices that are user-friendly and support a more independent lifestyle. The demand for products that offer ease of use and enhanced monitoring capabilities continues to rise, driven by technological advancements and consumer preferences.

### By Product Type: Analog Insulin Delivery Devices (Largest) vs. Continuous Glucose Monitoring Systems (Fastest-Growing)

In the US insulin delivery-devices market, the distribution of market share among the product types reveals that Analog Insulin Delivery Devices hold the largest segment. Their established presence and reliability make them the preferred choice among many healthcare providers and patients. Meanwhile, Pen-Needle Systems also contribute significantly, but they are overshadowed by the demand for Analog Insulin Delivery Devices and Continuous Glucose Monitoring Systems, which are gaining traction due to their advanced features and benefits.

Continuous Glucose Monitoring Systems are emerging as the fastest-growing segment, driven by the increasing prevalence of diabetes and the need for more effective management solutions. Technological advancements are making these devices more accessible and user-friendly, and healthcare professionals are increasingly recommending them for their accuracy and real-time monitoring capabilities. The growing awareness of diabetes management and preventive care further fuels the demand, positioning Continuous Glucose Monitoring Systems at the forefront of innovation in insulin delivery.

Delivery Devices: Analog Insulin (Dominant) vs. Continuous Glucose Monitoring (Emerging)

Analog Insulin Delivery Devices are characterized by their proven efficacy in delivering insulin with precision, making them the dominant choice for insulin-dependent individuals. These devices have a longer history of use, promoting trust among users and healthcare professionals. In contrast, Continuous Glucose Monitoring Systems represent an emerging trend in the market, focusing on real-time glucose level tracking. They offer convenience and enhanced safety through timely alerts and data analysis, appealing to a tech-savvy patient base. This shift toward advanced monitoring solutions signifies a transitional phase where traditional devices coexist with innovative technology.

### By Mode of Delivery: Subcutaneous Injection (Largest) vs. Inhaled Insulin (Fastest-Growing)

In the US insulin delivery-devices market, subcutaneous injection holds the largest market share, accounting for a significant majority of usage among patients. This mode of delivery is preferred for its ease of administration and widespread accessibility, making it the cornerstone of diabetes management. Conversely, inhaled insulin, while representing a smaller share, is rapidly gaining favor among patients looking for alternatives to needles. This segment's growth indicates a shift in preferences towards innovations that offer convenience and less discomfort. 

The demand for more user-friendly and efficient delivery methods is driving the growth of the inhaled insulin segment. As technology advances, inhaled forms of insulin are becoming more refined, appealing to new users and those seeking an improved patient experience. Additionally, education and awareness surrounding diabetes management have increased, pushing patients to consider alternative delivery methods to optimize their treatment plans. This trend suggests a robust future for both subcutaneous injections and inhaled insulin in the market.

Delivery Methods: Subcutaneous Injection (Dominant) vs. Intravenous Injection (Emerging)

Subcutaneous injection remains the dominant mode of delivery in the US insulin delivery-devices market, recognized for its effectiveness and patient compliance. It allows for self-administration, fostering independence among diabetes patients, and is widely supported by healthcare professionals. In contrast, intravenous injection is emerging as a viable alternative, particularly in clinical settings for patients requiring tight glucose control. While it currently holds a smaller market share, advancements in intravenous delivery devices and techniques are enhancing its appeal. Both methods cater to distinct needs in diabetes management, with subcutaneous injection being the more accessible choice for general use, whereas intravenous injection is becoming increasingly relevant for specialized medical interventions.

## Competitive Benchmarking

The insulin delivery-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for effective diabetes management solutions. Key players such as Medtronic (US), Abbott (US), and Insulet (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Medtronic (US) focuses on innovation through continuous product development, particularly in automated insulin delivery systems, while Abbott (US) emphasizes partnerships to expand its continuous glucose monitoring (CGM) technology. Insulet (US), known for its Omnipod system, is leveraging digital transformation to improve user experience and adherence, thereby shaping a competitive environment that prioritizes patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Novo Nordisk (DK) and Sanofi (FR) cannot be overlooked, as they continue to innovate and expand their product offerings, thereby intensifying competition.
In October Medtronic (US) announced the launch of its latest insulin pump, which integrates advanced AI algorithms to optimize insulin delivery based on real-time glucose data. This strategic move is significant as it positions Medtronic (US) as a leader in personalized diabetes management, potentially enhancing patient outcomes and solidifying its market share. The integration of AI into insulin delivery systems may also set a new standard for the industry, prompting competitors to accelerate their own technological advancements.
In September Abbott (US) revealed a partnership with a leading telehealth provider to enhance remote diabetes management services. This collaboration is crucial as it aligns with the growing trend of digital health solutions, allowing Abbott (US) to offer comprehensive care that extends beyond traditional product offerings. By integrating telehealth capabilities, Abbott (US) is likely to improve patient engagement and adherence, which could translate into increased market penetration.
In August Insulet (US) expanded its manufacturing capabilities by investing in a new facility in the Midwest. This strategic investment is indicative of Insulet's (US) commitment to scaling production in response to rising demand for its Omnipod system. The new facility is expected to enhance supply chain efficiency and reduce lead times, thereby positioning Insulet (US) favorably against competitors in a rapidly evolving market.
As of November current trends in the insulin delivery-devices market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage complementary strengths and enhance their product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the diverse needs of patients and healthcare providers.

## Recent News & Developments

The US Insulin Delivery Devices Market has witnessed significant advancements and developments recently. In August 2023, Medtronic announced its latest innovation in insulin delivery with the launch of the MiniMed 780G system, which offers automated insulin delivery to improve glycemic control in patients with diabetes.

Meanwhile, in June 2023, Dexcom introduced its G7 Continuous Glucose Monitoring system, further enhancing diabetes management through seamless integration with insulin delivery devices. Notably, in July 2023, Becton Dickinson completed its acquisition of the digital health company Atrial Medical, aiming to expand their portfolio in diabetes care.

A substantial valuation growth has been observed in companies such as Eli Lilly, which has significantly increased its market share due to its advancements in insulin formulations. The market has also seen mergers and collaborations to enhance research and development capabilities, as seen with Novo Nordisk’s partnership with Insulet Corporation.

The increasing prevalence of diabetes in the US has driven innovation and investment in insulin delivery technologies, reflecting strong growth in this critical sector of healthcare.

## Report Scope

| MARKET SIZE 2024 | 3709.79(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 3900.84(USD Million) |
| MARKET SIZE 2035 | 6445.22(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.15% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (US), Abbott (US), Roche (CH), Insulet (US), Novo Nordisk (DK), Sanofi (FR), Becton Dickinson (US), Ypsomed (CH), Tandem Diabetes (US) |
| Segments Covered | Device Type, End User, Product Type, Mode of Delivery |
| Key Market Opportunities | Integration of smart technology in insulin delivery-devices enhances patient adherence and management. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the insulin delivery-devices market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US insulin delivery-devices market?**
A: The market valuation was $3709.79 Million in 2024.

**Q: What is the projected market size for the US insulin delivery-devices market by 2035?**
A: The market is projected to reach $6445.22 Million by 2035.

**Q: What is the expected CAGR for the US insulin delivery-devices market during 2025 - 2035?**
A: The expected CAGR is 5.15% during the forecast period.

**Q: Which device type had the highest valuation in 2024?**
A: Insulin pens had a valuation of $1200.0 Million in 2024.

**Q: What are the projected valuations for insulin pumps by 2035?**
A: Insulin pumps are projected to reach $2000.0 Million by 2035.

**Q: Which end user segment is expected to dominate the market in 2035?**
A: Home care settings are projected to dominate with a valuation of $3000.0 Million by 2035.

**Q: What is the valuation range for continuous glucose monitoring systems in 2024?**
A: Continuous glucose monitoring systems had a valuation range of $1509.79 Million to $2445.22 Million in 2024.

**Q: Which company is a key player in the US insulin delivery-devices market?**
A: Medtronic is one of the key players in the market.

**Q: What is the valuation for subcutaneous injection devices in 2024?**
A: Subcutaneous injection devices had a valuation of $2000.0 Million in 2024.

**Q: What is the expected growth trend for insulin delivery devices in the coming years?**
A: The market is likely to experience steady growth, reaching $6445.22 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-insulin-delivery-devices-market-19958*